TBNHealth
STAT+: Does Isomorphic Labs have what it takes to revolutionize drugmaking?
Publication: STAT
Author: Allison DeAngelis
Source published: 19/10/2026, 08:30:00 UTC
Briefing created: 20/10/2026, 07:41:50 UTC
Based on a feed excerpt; full article content has not been acquired. Source evidence retrieved 20/10/2026, 07:22:24 UTC.
Briefings
In late 2024, Thrive Capital attempted to secure a stake in Isomorphic Labs, an Alphabet-affiliated startup focused on AlphaFold protein modeling. Despite the company's secrecy and lack of external funding, Klemmer's team persisted, viewing the potential to commercialize AI-driven drug discovery as economically valuable. The article notes that Isomorphic had previously held a Nobel Prize in chemistry for its work, but the current status of its commercialization remains uncertain.
Key points
- Thrive Capital's 18-month courtship campaign in late 2024 aimed to secure a stake in Isomorphic Labs, an Alphabet-affiliated startup focused on AlphaFold protein modeling.
- Isomorphic Labs had previously held a Nobel Prize in chemistry for its work, but the article does not confirm whether this technology is currently being actively used for drug development.
Context
The article discusses a late 2024 attempt by Thrive Capital to woo Isomorphic Labs, an Alphabet-affiliated startup focused on AlphaFold protein modeling. The finding matters because it highlights the tension between high-profile AI research and actual commercial application, specifically regarding the potential for AlphaFold to revolutionize drugmaking.
Limitations
The evidence is limited to a single article from late 2024. It does not provide data on the current status of Isomorphic Labs' drug development efforts, the specific timeline of the courtship campaign, or any quantitative metrics on the startup's progress. The article explicitly states that Isomorphic was not actively raising money and had kept outside investors at bay, but does not specify the outcome of the investment attempt.
Generated by Bittrees-hosted qwen35-2b sha256:aaf42c8b7c3c on 20/10/2026, 07:41:50 UTC. Based on publisher-provided feed evidence; may not cover the full original article. Check the source for details.
View archived briefing on IPFS
bafybeiax2mj4f673ugervpyjxkztjch6e7mswjzka6kabktip57zd4ut7u